Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + FulvestrantCompleted
NCT07008963N/AUpdated Feb 23, 2026
Sponsor: AstraZeneca
Metastatic Breast Cancer
United States
A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes PatientsCompleted
NCT02616666Phase 4Updated Feb 20, 2026
Sponsor: University of Liverpool
Type 2 Diabetes Mellitus
United Kingdom
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no LossActive Not Recruiting
NCT04065269Phase 2Updated Feb 20, 2026
Sponsor: Institute of Cancer Research, United Kingdom
Gynaecological Cancers
Canada, United Kingdom
Impact of Inhaled PT003 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD PatientTerminated
NCT04087590Phase 2Updated Feb 20, 2026
Sponsor: University Hospital, Lille
Copd
France
Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)Terminated
NCT04157335Phase 3Updated Feb 19, 2026
Sponsor: AstraZeneca
Nasal Polyposis · Eosinophilic Chronic Rhinosinusitis
United States, Argentina, Australia, Belgium, Bulgaria +12 more
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLCSuspended
NCT05403723Phase 1Updated Feb 19, 2026
Sponsor: University of Maryland, Baltimore
Extensive-stage Small-cell Lung Cancer
United States
A Study to Assess the Effect of AZD0780 on Ambulatory Blood PressureCompleted
NCT06692764Phase 2Updated Feb 18, 2026
Sponsor: AstraZeneca
Atherosclerotic Cardiovascular Disease
United States
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast CancerActive Not Recruiting
NCT04176848Phase 2Updated Feb 18, 2026
Sponsor: Canadian Cancer Trials Group
Breast Cancer
Canada
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.Recruiting
NCT07407465Phase 2Updated Feb 17, 2026
Sponsor: Gruppo Oncologico del Nord-Ovest
Colorectal Cancer · Colorectal Adenocarcinoma · Rectal Adenocarcinoma · Rectal Cancer, Adenocarcinoma
France, Germany, Italy, Spain
Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe ExacerbationCompleted
NCT07414134N/AUpdated Feb 17, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease
United States
A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With AsthmaActive Not Recruiting
NCT06502366Phase 3Updated Feb 13, 2026
Sponsor: AstraZeneca
Asthma
United States, China, Malaysia, Mexico, Thailand +1 more
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.Completed
NCT02000622Phase 3Updated Feb 13, 2026
Sponsor: AstraZeneca
Breast Cancer Metastatic · BRCA 1 Gene Mutation · BRCA 2 Gene Mutation
United States, Bulgaria, China, Czechia, France +14 more
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLLActive Not Recruiting
NCT03580928Phase 2Updated Feb 13, 2026
Sponsor: Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia (CLL)
United States
PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC TrialActive Not Recruiting
NCT02624973Phase 2Updated Feb 12, 2026
Sponsor: Haukeland University Hospital
Breast Cancer
Norway
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & NeckCompleted
NCT02499328Phase 1, Phase 2Updated Feb 11, 2026
Sponsor: AstraZeneca
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
United States, Belgium, Germany, Italy, Spain +1 more
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerCompleted
NCT02917993Phase 1, Phase 2Updated Feb 9, 2026
Sponsor: Incyte Corporation
Lung Cancer
United States, South Korea, Spain, Taiwan
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin LymphomasRecruiting
NCT04883437Phase 2Updated Feb 9, 2026
Sponsor: Emory University
Grade 1 Follicular Lymphoma · Grade 2 Follicular Lymphoma · Grade 3a Follicular Lymphoma · Indolent Non-Hodgkin Lymphoma
United States
FASENRA Regulatory Postmarketing Surveillance in KoreaCompleted
NCT05091333N/AUpdated Feb 6, 2026
Sponsor: AstraZeneca
Asthma, EGPA(Eosinophilic Granulomatosis With Polyangiitis)
South Korea
Clinical Evaluation of the Nova Max Pro StatSensor DeviceCompleted
NCT07392710NAUpdated Feb 6, 2026
Sponsor: Royal Free Hospital NHS Foundation Trust
Kidney Transplant · Kidney Disease, Chronic
United Kingdom
Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)Completed
NCT04930549Phase 2Updated Feb 6, 2026
Sponsor: University Hospital, Rouen
Renal Insufficiency, Chronic
France
Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled AsthmaCompleted
NCT05850494Phase 3Updated Feb 6, 2026
Sponsor: AstraZeneca
Asthma
United States
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790MCompleted
NCT03133546Phase 2Updated Feb 6, 2026
Sponsor: ETOP IBCSG Partners Foundation
Non Small Cell Lung Cancer Metastatic
Ireland, Netherlands, Singapore, South Korea, Spain +1 more
GEMINI-NSCLC: NSCLC Biomarker StudyRecruiting
NCT05236114N/AUpdated Feb 5, 2026
Sponsor: Tempus AI
Non-Small Cell Lung Cancer
United States
OptimAIR: Towards Right Care in Asthma Through Point-of-care Phenotyping, Guideline-based Assessment and Management Optimalisation Using the AsthmaOptimiser in Primary CareActive Not Recruiting
NCT07390669NAUpdated Feb 5, 2026
Sponsor: General Practitioners Research Institute
Asthma Control
Argentina, Chile, Spain
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's MacroglobulinemiaActive Not Recruiting
NCT04624906Phase 2Updated Feb 4, 2026
Sponsor: Sunnybrook Health Sciences Centre
Waldenstrom Macroglobulinemia
Canada

Previous page Next page